(Q34638302)

3 August 2017

title

Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection (English)

1 reference

3 August 2017

main subject

anti-retroviral agent

0 references

1 reference

Jaime Robertson

1

1 reference

3 August 2017

Judith Feinberg

series ordinal

2

1 reference

3 August 2017

language of work or name

English

0 references

publication date

17 May 2012

1 reference

Expert Opinion on Pharmacotherapy

3 August 2017

published in

1 reference

3 August 2017

volume

13

1 reference

3 August 2017

issue

9

1 reference

3 August 2017

page(s)

1363-1375

1 reference

Myelomeningocele in a child with intrauterine exposure to efavirenz.

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE st

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Boosted tipranavir versus darunavir in treatment-experienced patients: observational data from the randomized POTENT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Solid state characterization of the anti-HIV drug TMC114: interconversion of amorphous TMC114, TMC114 ethanolate and hydrate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Pharmacokinetics of once-daily etravirine without and with once-daily darunavir/ritonavir in antiretroviral-naive HIV type-1-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Forgiveness of non-adherence to HIV-1 antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Pharmacokinetics of once-daily darunavir-ritonavir and atazanavir-ritonavir over 72 hours following drug cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy of once-daily darunavir/ritonavir 800/100 mg in HIV-infected, treatment-experienced patients with no baseline resistance-associated mutations to darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Resistance profile of darunavir: combined 24-week results from the POWER trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Influence of baseline protease inhibitor resistance on the efficacy of darunavir/ritonavir or lopinavir/ritonavir in the TITAN trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Safety, Tolerability, and Efficacy of Darunavir (TMC114) with Low-Dose Ritonavir in Treatment-Experienced, Hepatitis B or C Co-infected Patients in POWER 1 and 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

Factors Associated With Virological Failure in HIV-1–Infected Patients Receiving Darunavir/Ritonavir Monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.681776

10.1517/14656566.2012.681776

21 January 2018

Identifiers

DOI

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ifobc7pau5fczbh22f6vmw7tvq

mapped directly with Wikidata item

30 July 2022

based on heuristic

Fatcat ID

release_ifobc7pau5fczbh22f6vmw7tvq

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ifobc7pau5fczbh22f6vmw7tvq

mapped directly with Wikidata item

30 July 2022

based on heuristic

https://api.fatcat.wiki/v0/release/ifobc7pau5fczbh22f6vmw7tvq

1 reference